Form 4: Medtronic Executive Michael Marinaro Receives Significant Equity Grants

Medtronic plc's EVP and President of MedSurg and Americas, Michael Marinaro, was granted restricted stock units, performance share units, and stock options effective July 28, 2025, as part of his compensation.

Summary

• Michael Marinaro, EVP, President of MedSurg and Americas at Medtronic plc, was granted 9,786 Ordinary Shares as Restricted Stock Units (RSUs) on July 28, 2025, which vest 100% on the third anniversary of the grant date.
• An additional 24,465 Performance Share Units (PSUs) were granted on July 28, 2025, representing a contingent right to receive one share of Medtronic common stock per unit, with performance conditions to be satisfied by April 28, 2028.
• The number of shares issued for PSUs can vary: 24,465 shares if target performance metrics are achieved, up to 48,930 shares for maximum performance, and 0 shares if minimum performance metrics are not met.
• Marinaro also received 69,005 Stock Options on July 28, 2025, with an exercise price of $91.97, which become exercisable at a rate of 25% per year beginning on the first anniversary of the grant date and expire on July 28, 2035.
• Following these reported transactions, Marinaro beneficially owns 51,093 Ordinary Shares, which includes 479 shares acquired through dividend reinvestment and 153 shares acquired under Medtronic's Employee Stock Ownership Plan since the last report.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged contract or instruction for the purchase or sale of equity securities.

Sentiment

Score: 8

Explanation: The grant of significant equity awards to a key executive is a positive signal of long-term commitment and aligns management's interests with shareholder value creation. This is a standard, positive event for executive compensation.

Positives

• The grant of restricted stock units, performance share units, and stock options aligns the executive's long-term financial interests with the company's performance and shareholder value creation.
• Equity-based compensation is a standard practice for executive remuneration, incentivizing leadership to achieve strategic goals and improve company profitability.
• The inclusion of performance share units ties a significant portion of the executive's compensation directly to the achievement of specific company performance metrics.

Negatives

• The future issuance of shares from these grants could lead to a degree of share dilution, though this is a common aspect of equity compensation plans.

Future Outlook

The filing details future vesting schedules and performance periods for the granted equity awards, indicating a long-term incentive structure for the executive. Performance Share Units are tied to future company performance metrics over a three-year period.

Industry Context

The granting of restricted stock units, performance share units, and stock options is a common and widely adopted practice in executive compensation across various industries, particularly in large, publicly traded corporations like Medtronic. This structure is designed to attract, retain, and motivate key executives by aligning their financial success with the long-term performance and strategic objectives of the company.

Comparison to Industry Standards

• The use of a mix of Restricted Stock Units (RSUs), Performance Share Units (PSUs), and Stock Options is a standard approach to executive compensation in large multinational corporations, including those in the medical technology and healthcare sectors.
• The vesting schedules (e.g., 3-year for RSUs, annual for options) and performance-based conditions for PSUs are typical for long-term incentive plans designed to encourage sustained performance and retention.
• Comparable companies in the medical device and healthcare industry, such as Johnson & Johnson, Abbott Laboratories, and Stryker Corporation, commonly utilize similar equity-based compensation structures for their senior executives to align interests with shareholders.

Corporate Governance

Related Party Transactions

• The equity grants are transactions between Medtronic plc and its executive, Michael Marinaro, which are considered related-party transactions as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for future dilution from the issuance of shares upon vesting of RSUs and PSUs, and exercise of options. However, the grants also align executive incentives with shareholder interests, potentially leading to improved company performance.
• Executive (Michael Marinaro): Receives significant long-term equity compensation, incentivizing continued dedication and performance aligned with company goals.

Next Steps

• Vesting of 9,786 Restricted Stock Units on the third anniversary of the grant date (July 28, 2028).
• Assessment of performance conditions for 24,465 Performance Share Units by April 28, 2028, determining the final number of shares to be issued.
• Stock options for 69,005 shares will begin to become exercisable at a rate of 25% per year starting on the first anniversary of the grant date (July 28, 2026).

Key Dates

Recommendation

This Form 4 details routine executive equity compensation grants. While these grants align executive incentives with shareholder interests, they do not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard compensation event.

Keywords

Medtronic, MDT, Michael Marinaro, executive compensation, restricted stock units, performance share units, stock options, insider transaction, Form 4, equity grant, Rule 10b5-1 plan